The S&P SmallCap 600 Index includes 600 companies, representing about 3% of the U.S. market.
For 2026, the company’s guidance reflected sales that assume a measured consumer environment.
JPMorgan analyst Bryan Smilek assigned a ‘Neutral’ rating with a $50 price target.
Last week, Telsey Advisory lowered the price target to $55 from $65 with a Market Perform rating following the company’s disappointing holiday sales and Q4 guidance
The company, whose shares rose 9% on Monday, said it intends to complete the share purchase in connection with its existing authorization of 68.5 million shares.
Kohl’s posted better-than-expected earnings, with earnings per share of $0.95, surpassing estimates of $0.72.
Wall Street analysts expect the company to post Q4 earnings per share of $3.52 on revenue of $3.78 billion.
The company cited an "uncertain" macro environment, a shift in consumer confidence, and headwinds from unseasonal weather in the U.S.
Annual revenue from its MS drug, Briumvi, more than tripled, with U.S. net product revenue reaching $103.6 million in the fourth quarter and $310 million for the full year.
CEO Adam Grossman highlighted a 65% year-over-year jump in total revenue and a staggering 309% increase in adjusted EBITDA for 2024.